Utrecht (The Netherlands), September 17th, 2024. At a joint event at the Innovation Center for Advanced Therapies (ICAT) on the Utrecht Science Park Zeist, representatives from four pioneering consortia supported by the Dutch National Growth Fund—NXTGEN Hightech, RegMed XB, Biotech Booster, and Oncode Accelerator— met to share their accomplishments to date and future plans. They also identified key areas for collaboration, and the productive day resulted in the drafting of a joint statement as well as a call for new partners.

All four consortia include a focus on innovating cell-based therapeutic products and approaches, such as those employed in regenerative medicine and immunotherapy, in order to provide novel treatments for a spectrum of diseases ranging from cancer to autoimmune diseases.

With the ultimate goal of bringing new therapeutics to patients, NXTGEN Hightech, RegMed XB, and Oncode Accelerator are also building, innovating, and scaling the technology and infrastructure necessary for production of these advanced therapy medicinal products (ATMPs) in the Netherlands. Biotech Booster, a National Growth Fund program established to support the commercialization of biotechnology findings in The Netherlands, will be a key collaborator to bring innovative medicines developed within the consortia to market as quickly as possible.

We are grateful for the opportunity to co-organize this impactful event where insights, achievements, future goals, and key areas for collaboration were discussed. We are excited about the continued progress with these consortia as we work together to transforming healthcare and deliver innovative therapies to the market.

The full newsletter can be found here: https://lnkd.in/eSDPi5dE.